Congenica, a global provider of clinical genomics interpretation software, today announced the appointment of its new Chief Executive Officer David Atkins, Ph.D. Based at the Companys headquarters in Cambridge, UK, Dr Atkins also joins Congenicas Board of Directors.
EU ombudsman soft-sells safety concerns on HPV jabs
BackgroundA complaint against the EMAs handling of a referral procedure related to potential side effects of Sanofi/MSDs HPV vaccine Gardasil and GSKs HPV jab Cervarix, filed by the Nordic Cochrane Centre and physicians, has been rejected by the European Ombudsman.
Storm Therapeutics Appoints Nobel Prize Winner Thomas Cech as Scientific Advisor
AppointmentsStorm Therapeutics today announced the appointment of Nobel Prize Winner Professor Thomas Cech as a Scientific Advisor. This appointment follows STORM Therapeutics successful Series A Financing Extension announced in January 2018.
Sanofi acquiring Ablynx
Latest NewsBriefly after Belgian nanobody maker Ablynx rejected a €2.3bn take-over bid of Novo, its board accepted a €3.9bn tender of its R&D partner Sanofi. It’s the second large take-over of Sanofi this month.
EMA recommends seven new drugs for market
Latest NewsThe European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) greenlighted seven medicines for approval at its January 2018 meeting, including one orphan medicine, and one biosimilar.
Congenica Appoints New CEO
AppointmentsCongenica, a global provider of clinical genomics interpretation software, today announced the appointment of its new Chief Executive Officer David Atkins, Ph.D. Based at the Companys headquarters in Cambridge, UK, Dr Atkins also joins Congenicas Board of Directors.
New wave of optimism for European biotech stocks
BackgroundThe European biotech stock market witnessed an increase in IPO and follow-on financing volumes in 2017. According to the new BIOCOM capital market report, published in November during BIO-Europe in Berlin, more than half the money was raised on the US Nasdaq. Within Europe, Euronext is still is the most attractive location – but Stockholm is catching up.
Bacterium blocks dengue and Zika virus transmission
Latest NewsScientists at the University of Glasgow have found a bacterial strain which blocks dengue and Zika virus transmission from mosquitoes.
Novartis in US$170m licence deal with Spark Therapeutics
Latest NewsNovartis AG has strengthened its ophtalmology portfolio by acquiring a licence for Spark Therapeutics voretigene neparvovec (Luxturna), an FDA-approved gene therapy that corrects mutations in RPE65, which leads to juvenile blindness in homozygotous carriers.
Connectivity is the future
OpinionPharmaPack 2018:?The promises of digitalised medicine dont stop at injection pens or autoinjectors. One of the early adopters in the field is Swiss Haselmeier AG (Pharmapack: hall 7.1, booth L19). European Biotechnology spoke with Paul E. Jansen, Member of the Board, from Haselmeiers Boston office about how connected devices could define a new paradigm in therapy compliance and control of chronic diseases, and how they will shape the market.
Emil Billbäck appointed CEO of BONESUPPORT
AppointmentsBONESUPPORT (Nasdaq Stockholm: BONEX) announces that the Board of Directors has appointed Emil Billbäck as the new CEO of BONESUPPORT HOLDING AB. Mr. Billbäck has over 20 years management experience from the life science industry and the Board of Directors is of the opinion that he has the ideal profile to implement the Companys strategy and to deliver shareholder value. He will join BONESUPPPORT on 1st March 2018 when he will replace Richard Davies who has been the Companys CEO since January 2016.